Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients

References

• Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581–92.
   PubMed Web of Science ®Google Scholar
• Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008;47:20–31.
   PubMed Web of Science ®Google Scholar
• Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004;54:295–308.
   PubMed Web of Science ®Google Scholar
• Sturgeon MC, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11–e79.
   PubMed Web of Science ®Google Scholar
• Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25–40.
   PubMed Web of Science ®Google Scholar
• Werb Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997;91:439–42.
   PubMed Web of Science ®Google Scholar
• Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: Biology and regulation. Cell Mol Life Sci 1999;56:104–32.
   PubMed Web of Science ®Google Scholar
• Ganesh SJ, Sier C, Heerding M, Griffioen G, Lamers C, Verspaget H. Urokinase receptor and colorectal cancer survival. Lancet 1994;344(8919):401–2.
   PubMed Web of Science ®Google Scholar
• Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, . Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54: 4671–5.
   PubMed Web of Science ®Google Scholar
• Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932–43.
   PubMed Web of Science ®Google Scholar
• Ohtani H, Pyke C, Dano K, Nagura H. Expression of urokinase receptor in various stromal-cell populations in human colon cancer: Immunoelectron microscopical analysis. Int J Cancer 1995;62:691–6.
   PubMed Web of Science ®Google Scholar
• Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Dano K, . Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009;124: 1860–70.
   PubMed Web of Science ®Google Scholar
• Konno H, Abe J, Kaneko T, Baba M, Shoji A, Sunayama K, . Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn J Cancer Res 2001;92:516–23.
   PubMedGoogle Scholar
• Hoyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007;44:65–102.
   PubMed Web of Science ®Google Scholar
• Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, . Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 1999;91:869–74.
   PubMed Web of Science ®Google Scholar
• Piironen T, Laursen B, Pass J, List K, Gardsvoll H, Ploug M, . Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004;50:2059–68.
   PubMed Web of Science ®Google Scholar
• Almasi CE, Hoyer-Hansen G, Christensen IJ, Dano K, Pappot H. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 2005;48:349–55.
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H. Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg 2002;89:1416–22.
   PubMed Web of Science ®Google Scholar
• Lomholt AF, Hoyer-Hansen G, Nielsen HJ, Christensen IJ. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Br J Cancer 2009;101:992–7.
   PubMed Web of Science ®Google Scholar
• Almasi CE, Hoyer-Hansen G, Christensen IJ, Pappot H. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS 2009;117:755–61.
   PubMed Web of Science ®Google Scholar
• Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785–93.
   PubMed Web of Science ®Google Scholar
• Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008;3:CD005390.
   Google Scholar
• Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brunner N, . Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006;52:838–44.
   PubMed Web of Science ®Google Scholar